Log in

Relevant bibliographies by topics / Antileukotriene drug / Journal articles

To see the other types of publications on this topic, follow the link: Antileukotriene drug.

Journal articles on the topic 'Antileukotriene drug'

Author: Grafiati

Published: 7 June 2025

Last updated: 16 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Antileukotriene drug.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Simsova, V. A., A. Yu Ovchinnikov, N. A. Miroshnichenko, and V. A. Ryabinin. "Antileukotriene drugs as a tool for improving the quality of life in patients with allergic rhinitis." Meditsinskiy sovet = Medical Council, no. 20 (November 18, 2022): 134–38. http://dx.doi.org/10.21518/2079-701x-2022-16-20-134-138.

Full text

Abstract:

Introduction. Allergic rhinitis (AR) is immunoglobulin E (IgE) mediated disease. Which, after exposure to allergens, manifests itself with various symptoms such as sneezing, runny nose, nasal itching, and nasal congestion, which seriously affects the quality of life of patients. In some patients, AR poses a risk of developing serious mental disorders. Currently, various medicines are used for treatment. Objective. Consideration of the effectiveness of AR therapy with antileukotriene drugs, depending on the mental state of the patient. Materials and methods. The study involved 200 people diagno

APA, Harvard, Vancouver, ISO, and other styles

2

Kamaev, A. V., О. V. Trusova, and I. A. Kamaeva. "Age-related evolution of bronchial asthma in pediatric practice and approaches to improving prognosis." Meditsinskiy sovet = Medical Council, no. 11 (August 12, 2021): 78–86. http://dx.doi.org/10.21518/2079701x-2021-11-78-86.

Full text

Abstract:

The main high-risk group for a diagnosis of bronchial asthma (BA) are children with recurrent obstructive bronchitis, complicated by a widespread form of acute respiratory viral infections. Basic therapy of BA is aimed at suppressing inflammation of the bronchial wall. In addition to inhaled glucocorticosteroids, the antileukotriene drug montelukast has a proven anti-inflammatory effect. This article discusses published work on the effect of montelukast on inflammation biomarkers in real clinical practice and remodeling of the bronchial wall in the experiment. A comparative study of the clinic

APA, Harvard, Vancouver, ISO, and other styles

3

Il`ina, Natalya I., Oksana M. Kurbacheva, Natalya M. Nenasheva, et al. "Efficacy and safety of the antileukotriene drugs: relevant data. RAACI experts conclusion." Russian Journal of Allergy 17, no. 3 (2020): 121–29. http://dx.doi.org/10.36691/rja1395.

Full text

Abstract:

In many countries of the world and in Russia, in particular, the pharmacological use of antagonists of cysteinyl receptors LT1 (CysLTR) is a long-proven and well-proven pharmacotherapy of bronchial asthma (BA) and allergic rhinitis (AR) in adults and children. Among antileukotriene drugs the most commonly used medication for the treatment of these diseases is the original montelukast, which is considered a safe drug associated with the appearance of only a few adverse reactions, usually not differing in type and frequency from those that occur with placebo. Currently, there are a large n

APA, Harvard, Vancouver, ISO, and other styles

4

Spanbroek, R., and A. J. Habenicht. "The potential role of antileukotriene drugs in atherosclerosis." Drug News & Perspectives 16, no. 8 (2003): 485. http://dx.doi.org/10.1358/dnp.2003.16.8.829345.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Iwona, Stelmach, and Grzelewski Tomasz. "Antileukotriene Treatment in Children with Asthma - New Patents." Recent Patents on Inflammation & Allergy Drug Discovery 2, no. 3 (2008): 202–11. http://dx.doi.org/10.2174/187221308786241938.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Korkmazov, M. Yu, M. A. Lengina, I. D. Dubinets, A. M. Korkmazov, and A. A. Smirnov. "Opportunities for correction of individual links of the pathogenesis of allergic rhinitis and bronchial asthma with assessment of the quality of life of patients." Meditsinskiy sovet = Medical Council, no. 4 (April 5, 2022): 24–34. http://dx.doi.org/10.21518/2079-701x-2022-16-4-24-34.

Full text

Abstract:

Introduction. One of the antileukotriene drugs for the treatment of bronchial asthma and allergic rhinitis with and without polyposis is montelukast. The presented article presents the results of the analysis of the effectiveness, safety and impact on the quality of life of patients, the use of the singular, in various forms of allergic rhinitis and associated comorbid conditions.Aim of the study. To assess the impact on the quality of life of patients, the effectiveness and safety of the use of montelukast in the complex therapy of patients with allergic rhinitis and comorbid diseases.Materia

APA, Harvard, Vancouver, ISO, and other styles

7

Zyryanov, S. K., and O. I. Butranova. "Genetically engineered drugs for treatment of bronchial asthma: recent achievements." Russian Pulmonology 28, no. 5 (2018): 584–601. http://dx.doi.org/10.18093/0869-0189-2018-28-5-584-601.

Full text

Abstract:

Current population of patients with asthma is characterized by increasing resistance to standard pharmacotherapeutic agents such as inhaled corticosteroids, antileukotriene agents and anti-IgE antibodies. These findings were confirmed by international statistic data and indicate insufficient efficacy of the treatment. Asthma phenotyping encompassing a role of certain biomarkers for bronchial inflammation could contribute to achieving better response to treatment. Genetically engineered drugs could directly impact on mediators and modulators involved in the inflammation and bronchoconstriction.

APA, Harvard, Vancouver, ISO, and other styles

8

Savelieva, Olga, Alexandra Karunas, Inga Prokopenko, et al. "Evaluation of Polygenic Risk Score for Prediction of Childhood Onset and Severity of Asthma." International Journal of Molecular Sciences 26, no. 1 (2024): 103. https://doi.org/10.3390/ijms26010103.

Full text

Abstract:

Asthma is a common complex disease with susceptibility defined through an interplay of genetic and environmental factors. Responsiveness to asthma treatment varies between individuals and is largely determined by genetic variability. The polygenic score (PGS) approach enables an individual risk of asthma and respective response to drug therapy. PGS models could help to predict the individual risk of asthma using 26 SNPs of drug pathway genes involved in the metabolism of glucocorticosteroids (GCS), and beta-2-agonists, antihistamines, and antileukotriene drugs associated with the response to a

APA, Harvard, Vancouver, ISO, and other styles

9

Wsól, Vladimír, Barbora Szotáková, Vendula Baliharová, et al. "The Phase I Biotransformation of the Potential Antileukotrienic Drug Quinlukast in Rat Microsomes and Hepatocytes." Collection of Czechoslovak Chemical Communications 69, no. 3 (2004): 689–702. http://dx.doi.org/10.1135/cccc20040689.

Full text

Abstract:

The phase I metabolism of quinlukast (VÚFB 19363, Q; 4-{[4-(2-quinolylmethoxy)phenyl]- sulfanyl}benzoic acid), a new antiasthmatic drug with significant antileukotriene effects, was investigated in rat microsomes and hepatocytes. Quinlukast, incubated with rat liver microsomal fraction under oxidative conditions, generated four metabolites, M2-M5. Based on comparison with synthetically prepared standards, metabolites M2 and M4 were identified as sulfoxide and sulfone of the parent compound, respectively. Metabolites M3 and M5 were identified as quinlukast dihydrodiols. For all the metabolites

APA, Harvard, Vancouver, ISO, and other styles

10

Asmanov, A. I., N. G. Konyukova, N. D. Pivneva, Yu V. Grebennikova, and A. N. Pampura. "Comprehensive treatment method for children with allergic rhinitis." Russian Medical Inquiry 5, no. 5 (2021): 348–52. http://dx.doi.org/10.32364/2587-6821-2021-5-5-348-352.

Full text

Abstract:

Allergic rhinitis (AR) is a common childhood disease. At the same time, there is an underdiagnosis of this condition in the clinical practice and its significant impact on the life quality of the patient and his family. The article describes a modern stepwise approach in complex AR therapy in children. This approach involves the choice of drug therapy in accordance with the disease course. In this case, it is necessary, in particular, to take into account the clinically significant sensitization profile, the presence of concomitant allergic and non-allergic pathology, the patterns of the expec

APA, Harvard, Vancouver, ISO, and other styles

11

Glushkova, Evgeniya F., and Tatiana N. Surovenko. "Is it always easy for children with mild asthma?" Meditsinskiy sovet = Medical Council, no. 1 (March 21, 2021): 203–12. http://dx.doi.org/10.21518/2079-701x-2021-1-203-212.

Full text

Abstract:

Bronchial asthma is the most common chronic disease of children, the worst way is their quality of life. Compliance in the treatment of children is very important, since the actual effect of a drug is determined by both the effective drugs and patient adherence and correct use. A relevant test is the use of mild asthma, which is able to control bronchial hyperreactivity associated with exercise, cold air, and other nonspecific irritants (smoke, odors, etc.). Planning of baseline therapy for children with mild asthma aged 5 years old and younger is particularly problematic for paediatricians du

APA, Harvard, Vancouver, ISO, and other styles

12

Steinhilber, D. "5-Lipoxygenase: A Target for Antiinflammatory Drugs Revisited." Current Medicinal Chemistry 6, no. 1 (1999): 71–85. http://dx.doi.org/10.2174/0929867306666220207211259.

Full text

Abstract:

Abstract: Arachidonate 5-lipoxygenase is the key enzyme in leukotriene biosynthesis and catalyzes the initial steps in the conversion of arachidonic acid to biologically active leukotrienes. Leukotrienes are considered as potent potent mediators of inflammatory and allergic reactions which are locally released by leukocytes and other 5-LO expressing cells and exert their effects via binding to specific membrane receptors and, as suggested recently, the nuclear receptor PPARa. Because of the proinflammatory profile of leukotrienes it was assumed that leukotriene biosynthesis inhibitors and leuk

APA, Harvard, Vancouver, ISO, and other styles

13

Roos, Jessica, Marcus Peters, Isabelle V. Maucher, et al. "Drug-Mediated Intracellular Donation of Nitric Oxide Potently Inhibits 5-Lipoxygenase: A Possible Key to Future Antileukotriene Therapy." Antioxidants & Redox Signaling 28, no. 14 (2018): 1265–85. http://dx.doi.org/10.1089/ars.2017.7155.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Anthonisen, NR, K. Woodlrage, and J. Manfreda. "Use of Spirometry and Respiratory Drugs in Manitobans Over 35 Years of Age with Obstructive Lung Diseases." Canadian Respiratory Journal 12, no. 2 (2005): 69–74. http://dx.doi.org/10.1155/2005/974678.

Full text

Abstract:

BACKGROUND: Previous data indicated that spirometry was underused in people with obstructive disease, especially those with chronic obstructive pulmonary disease (COPD).OBJECTIVE: To examine the use of respiratory drugs in patients with COPD and asthma, and to relate drug use to spirometry.METHODS: Manitoba Health maintains a database of physician services remunerated by fees that includes spirometry. The database contains the diagnosis and patient identifiers, as well as sex, date of birth and residential postal code. Similar identifiers are used in the provincial pharmacare program that reco

APA, Harvard, Vancouver, ISO, and other styles

15

Санникова, Н. Н., С. Н. Артишевский, and В. Э. Сушинский. "A New Drag for the Treatment of Allergic Rhinitis." Рецепт 27, no. 2 (2024): 288–98. http://dx.doi.org/10.34883/pi.2024.27.2.013.

Full text

Abstract:

Аллергический ринит – самое распространенное аллергическое заболевание. Тесалин – новый препарат растительного происхождения, предназначенный для лечения аллергического ринита. Для изучения механизмов действия препарата Тесалин проведены исследования, которые позволяют предположить, что основой его фармакологической активности является ингибирование синтеза лейкотриенов, гистамина и интерлейкинов. Клинические исследования показали эффективность и безопасность препарата Тесалин как у взрослых пациентов, так и у детей. Для сравнения эффективности широко используемых антигистаминных препаратов и

APA, Harvard, Vancouver, ISO, and other styles

16

Оkhotnikova, O. M. "Efficiency of Using Antiinflammatory Drug with Antileukotriene Action — Montelukast Sodium as a Mean of Controlled Therapy of Bronchial Asthma and Allergic Rhinitis in Children." CHILD`S HEALTH, no. 4.72 (July 13, 2016): 19. http://dx.doi.org/10.22141/2224-0551.4.72.2016.76585.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Vakulenko, L. I., S. V. Samsonenko, and K. V. Skriabina. "Is chronic urticaria or urticarial vasculitis a diagnostic dilemma?" Modern pediatrics. Ukraine, no. 2(138) (March 28, 2024): 133–40. http://dx.doi.org/10.15574/sp.2024.138.133.

Full text

Abstract:

Introduction. Urticarial vasculitis (UV) is a rare disease that has two components: clinical manifestations of urticaria and histopathological signs of cutaneous leukocytoclastic vasculitis of small vessels, predominantly involving postcapillary venules. This condition is characterized by chronic or recurrent episodes of urticaria, each element of which lasts more than 24 hours and is accompanied by a feeling of pain and burning. The aim is to reveal the key points of pathogenetic mechanisms, differential diagnosis and therapeutic tactics of UV based on a clinical case. Clinical case. A clinic

APA, Harvard, Vancouver, ISO, and other styles

18

Dytyatkovska, Y., I. Rodkina, M. Yevtushenko, et al. "Efficacy of combination of antihistaminic agents and blocker of leukotriene receptors in the treatment of pollinosis exacerbation with bronchial asthma attacks." Medicni perspektivi 23, no. 1 part 1 (2018): 44–50. https://doi.org/10.26641/2307-0404.2018.1(part1).127208.

Full text

Abstract:

We have been observing 60 pollinosis patients at the age of 19 to 64 years with clinical manifestations of rhinitis, conjunctivitis, bronchial asthma. The study was conducted in the design of parallel groups. All patients were divided into 2 clinical groups (main and control), depending on the treatment regimen. The main group included 40 patients who received a combined drug Glencet Advance 1 tab. in the evening for 1 month. 20 patients included in the control group received symptomatic local therapy (eye drops, IGCC), β<sub>2</sub>-short-acting agonists. Results: integral assessment of

APA, Harvard, Vancouver, ISO, and other styles

19

Ebrahim, Nesrine, Yasser Mandour, Ayman Farid, et al. "Adipose Tissue-Derived Mesenchymal Stem Cell Modulates the Immune Response of Allergic Rhinitis in a Rat Model." International Journal of Molecular Sciences 20, no. 4 (2019): 873. http://dx.doi.org/10.3390/ijms20040873.

Full text

Abstract:

This study was designed to investigate the potential effects and underlying mechanism of adipose tissue-derived mesenchymal stem cells (MSCs) on allergic inflammation compared to Montelukast as an antileukotriene drug in a rat model of allergic rhinitis (AR). The effect of MSCs was evaluated in albino rats that were randomly divided into four (control, AR, AR + Montelukast, and AR + MSCs) groups. Rats of AR group were sensitized by ovalbumin (OVA) and then challenged with daily nasal drops of OVA diluted in sterile physiological saline (50 μL/nostril, 100 mg/mL, 10% OVA) from day 15 to day 21

APA, Harvard, Vancouver, ISO, and other styles

20

Selvadurai, Hiran, and Craig Mellis. "Antileukotriene Drugs in Childhood Asthma." Paediatric Drugs 2, no. 5 (2000): 367–72. http://dx.doi.org/10.2165/00128072-200002050-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Savlevich, E. L., O. M. Kurbacheva, A. V. Zurochka, E. S. Mitrofanova, Yu S. Smolkin, and E. V. Lyubimova. "The role of leukotriene receptor blockers in the treatment of allergic rhinitis in combination with chronic rhinosinusitis with nasal polyps." Meditsinskiy sovet = Medical Council, no. 8 (May 17, 2022): 111–16. http://dx.doi.org/10.21518/2079-701x-2022-16-8-111-116.

Full text

Abstract:

Background. Leukotrienes play an important role in the pathogenesis of allergic rhinitis (AR) and eosinophilic type of chronic rhinosinusitis with nasal polyps (CRSwNP). There is a phenotype of CRSwNP in combination with AR, which has specifics of local inflammation.The aim of our study was to investigate the efficacy of using an antileukotriene drug in the treatment of AR in combination with CRSwNP.Materials and methods. 63 patients with AR and bilateral CRSwNP after endoscopic bilateral polypotomy were randomly divided into 2 groups. In the 1st group 32 people (age 50.28 ± 1.37 years) were p

APA, Harvard, Vancouver, ISO, and other styles

22

In, Kwang Ho. "New Drugs for Asthma: Antileukotrienes." Tuberculosis and Respiratory Diseases 45, no. 5 (1998): 924. http://dx.doi.org/10.4046/trd.1998.45.5.924.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Szczeklik, Andrzej. "May the Force be with antileukotriene drugs." Pneumonologia i Alergologia Polska 78, no. 1 (2010): 1–2. http://dx.doi.org/10.5603/arm.27746.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

G. Riccioni, T. Bucciarelli, B. Mancini, C. Di Ilio, and N. D'Orazio. "Antileukotriene Drugs: Clinical Application, Effectiveness and Safety." Current Medicinal Chemistry 14, no. 18 (2007): 1966–77. http://dx.doi.org/10.2174/092986707781368522.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Mastalerz, Lucyna, and Jagoda Kumik. "Antileukotriene drugs in the treatment of asthma." Polish Archives of Internal Medicine 120, no. 3 (2010): 103–8. http://dx.doi.org/10.20452/pamw.899.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Wenzel, Sally E. "Antileukotriene Drugs in the Management of Asthma." JAMA 280, no. 24 (1998): 2068. http://dx.doi.org/10.1001/jama.280.24.2068.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Urso, Domenico Lorenzo, Daniele Vincenzo, Lorenzo Formaro, Ada Federico, and Giuseppe Urso. "Role of antileukotrienes in acute asthma exacerbations." Reviews in Health Care 3, no. 2 (2012): 75. http://dx.doi.org/10.7175/rhc.1553275-81.

Full text

Abstract:

Acute asthma exacerbations are one of the most frequent reasons to visit the emergency department or general practitioner. Although current standard treatments for acute asthma – including supplemental oxygen, short-acting β2-agonists, systemic corticosteroids and anticholinergics – are quite effective in most patients, they are inadequate for rapid and sustained improvement in a significant proportion. The antileukotrienes, a relatively new class of drugs, have a role in the treatment of chronic asthma. Their relatively rapid onset of action after endovenous or oral administration and their a

APA, Harvard, Vancouver, ISO, and other styles

28

Urso, Domenico Lorenzo, Daniele Vincenzo, Lorenzo Formaro, Ada Federico, and Giuseppe Urso. "Role of antileukotrienes in acute asthma exacerbations." Reviews in Health Care 3, no. 2 (2012): 75–81. http://dx.doi.org/10.7175/rhc.v3i2.155.

Full text

Abstract:

Acute asthma exacerbations are one of the most frequent reasons to visit the emergency department or general practitioner. Although current standard treatments for acute asthma – including supplemental oxygen, short-acting β2-agonists, systemic corticosteroids and anticholinergics – are quite effective in most patients, they are inadequate for rapid and sustained improvement in a significant proportion. The antileukotrienes, a relatively new class of drugs, have a role in the treatment of chronic asthma. Their relatively rapid onset of action after endovenous or oral administration and their a

APA, Harvard, Vancouver, ISO, and other styles

29

Smith, Lewis J. "Comparative Efficacy of Inhaled Corticosteroids and Antileukotriene Drugs in Asthma." BioDrugs 15, no. 4 (2001): 239–49. http://dx.doi.org/10.2165/00063030-200115040-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Nenasheva, N. M. "ROLE OF ANTILEUKOTRIENE DRUGS IN ACHIEVEMENT OF BRONCHIAL ASTHMA CONTROL." Medical Council, no. 18 (January 1, 2017): 44–55. http://dx.doi.org/10.21518/2079-701x-2017-18-44-55.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Claesson, H. ‐E, and S. ‐E Dahlén. "Asthma and leukotrienes: antileukotrienes as novel anti‐asthmatic drugs." Journal of Internal Medicine 245, no. 3 (1999): 205–27. http://dx.doi.org/10.1046/j.1365-2796.1999.00418.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Mastalerz, Lucyna, and Aleksander Kania. "Antileukotriene drugs in the treatment of obstructive lung diseases and rhinitis." Pneumonologia i Alergologia Polska 78, no. 1 (2010): 74–78. http://dx.doi.org/10.5603/arm.27759.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Grayson, Mitchell H., and Phillip E. Korenblat. "The role of antileukotriene drugs in management of rhinitis and rhinosinusitis." Current Allergy and Asthma Reports 7, no. 3 (2007): 209–15. http://dx.doi.org/10.1007/s11882-007-0074-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Mizernitskiy, Yu L., and A. I. Petrova. "Montelukast: results and prospects for applications in pediatric practice." Meditsinskiy sovet = Medical Council, no. 1 (February 26, 2024): 82–88. http://dx.doi.org/10.21518/ms2024-026.

Full text

Abstract:

The Centers for Disease Control and Prevention reports that more than 4 million children have been diagnosed with asthma. Currently, there is no treatment that could prevent the development of asthma or change its natural course over long-term follow-up. However, the disease can be controlled using treatments used in clinical practice. For persistent asthma in children aged 5 years and younger, low doses of inhaled glucocorticosteroids are recommended, as well as the administration of montelukast, a leukotriene receptor antagonist. In addition, montelukast is prescribed to patients with allerg

APA, Harvard, Vancouver, ISO, and other styles

35

Riccioni, G., F. Santilli, N. D'Orazio, et al. "The Role of Antileukotrienes in the Treatment of Asthma." International Journal of Immunopathology and Pharmacology 15, no. 3 (2002): 171–82. http://dx.doi.org/10.1177/039463200201500303.

Full text

Abstract:

Cysteinyl leukotrienes (Cys-LTs) are mediators released in asthma and are both direct bronchoconstrictors and proinflammatory substances that mediated several steps in the pathophysiology of chronic asthma, including inflammatory cells recruitment, vascular leakage, and possibly airway remodelling. Available evidence from clinical trials and real-word experience derived from managing patients with asthma justifies a broader role for anti-LTRAs in asthma management than that recommended in the National Asthma Education and Prevention Programm (NAEPP) and National Health Lung and Blood Institute

APA, Harvard, Vancouver, ISO, and other styles

36

Yakhontov, L. N., M. �. Kaminka, L. I. Mastafanova, V. B. Nikitin, and V. A. Azimov. "Leukotrienes and antileukotrienic preparations: Trends in the search and medical applications (review)." Pharmaceutical Chemistry Journal 21, no. 10 (1987): 700–710. http://dx.doi.org/10.1007/bf00758130.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Kupkina, A. V. "Efficacy of antileukotriene drugs for the treatment of bronchial asthma in overweight and obese children." CHILD`S HEALTH 15, no. 6 (2020): 434–43. http://dx.doi.org/10.22141/2224-0551.15.6.2020.215529.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Козловский, А. А. "Коморбидность ОРВИ и бронхиальной астмы у детей: особенности профилактики и лечения". Рецепт 28, № 2 (2025): 176–84. https://doi.org/10.34883/pi.2025.28.2.009.

Full text

Abstract:

Статья посвящена проблеме коморбидности острых респираторных вирусных инфекций и бронхиальной астмы у детей. Бронхообструктивный синдром на фоне респираторной инфекции у детей раннего возраста существенно повышает риск развития бронхиальной астмы в дальнейшем. Представлены данные медицинской литературы, указывающие на клиническую эффективность и безопасность терапии и профилактики ОРВИ, в том числе у пациентов с бронхиальной астмой, противовирусными препаратами (Гроприносин (инозин пранобекс)) и ингибиторами антилейкотриеновых рецепторов (Синглон (монтелукаст)). he article is devoted to the pr

APA, Harvard, Vancouver, ISO, and other styles

39

Junek, Richard, Bohumila Brůnová, Miloslav Kverka, Vladimíra Panajotová, Antonín Jandera, and Miroslav Kuchař. "Antileukotrienic N-arylethyl-2-arylacetamides in the treatment of ulcerative colitis." European Journal of Medicinal Chemistry 42, no. 8 (2007): 1084–94. http://dx.doi.org/10.1016/j.ejmech.2007.01.014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Junek, Richard, Miloslav Kverka, Antonín Jandera, et al. "Antileukotrienic phenethylamido derivatives of arylalkanoic acids in the treatment of ulcerative colitis." European Journal of Medicinal Chemistry 44, no. 1 (2009): 332–44. http://dx.doi.org/10.1016/j.ejmech.2008.02.030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Yakovleva, O. A., A. I. Semenenko, and O. Yu Hoina-Kardasevich. "New targets of pharmacotherapy of bronchial obstruction." Infusion & Chemotherapy, no. 3.1 (October 11, 2020): 87–88. http://dx.doi.org/10.32902/2663-0338-2020-3.1-73.

Full text

Abstract:

Objective. To assess the prospects for scientific development of new classes of bronchodilators for respiratory diseases with obstructive syndrome, taking into account future molecular targets. Materials and methods. The analysis of international English scientific information in the systems of surveys and search on the Internet for the last 5 years is carried out. Results and discussion. Currently, there is an increasing interest in the development of new directions for pharmacological correction of the mechanisms of bronchial obstruction. The proposed international protocols are

APA, Harvard, Vancouver, ISO, and other styles

42

Netopilová, Miloslava, Jaroslav Dršata, Martin Beránek, and Vladimír Palička. "New Potential Nonsteroidal Anti-Inflammatory Drugs with Antileukotrienic Effects: Influence on Model Proteins with Catalytic Activity." Acta Medica (Hradec Kralove, Czech Republic) 45, no. 1 (2002): 7–12. http://dx.doi.org/10.14712/18059694.2019.50.

Full text

Abstract:

Unspecific and side effects caused by interaction with proteins belong to common problems of many structures synthesized as potential medicaments. Possible in vitro interactions with proteins of a group of phenylsulfonyl benzoic acid derivatives (VÚFB 19363, 19369, 19370, 19371, and 19760) as new potential anti-inflammatory compounds with antileukotrienic activities were studied in the present work. Three purified enzymes were used as model proteins with catalytic activities: Pig heart aspartate aminotransferase (AST, EC 2.6.1.1), alanine aminotransferase (ALT, EC 2.6.1.2), and glutamate decar

APA, Harvard, Vancouver, ISO, and other styles

43

Levchenko, A. R. "The effectiveness of antihistamine and antileukotriene drugs in the treatment of irritable bowel syndrome with the reveled concomitant allergic conditions." Modern Gastroenterology, no. 2 (April 25, 2019): 22–28. http://dx.doi.org/10.30978/mg-2019-2-22.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Stryjewska-Makuch, Grażyna, Maria Humeniuk-Arasiewicz, Edyta Jura-Szołtys, and Joanna Glück. "The Effect of Antileukotrienes on the Results of Postoperative Treatment of Paranasal Sinuses in Patients with Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease." International Archives of Allergy and Immunology 179, no. 4 (2019): 281–89. http://dx.doi.org/10.1159/000499134.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Dršata, Jaroslav, and Miroslav Kuchař. "Inhibition of Aromatic Amino Acid Decarboxylase by a Group of New Potential Nonsteroidal Anti-Inflammatory Drugs with Antileukotrienic Effects." Acta Medica (Hradec Kralove, Czech Republic) 46, no. 4 (2003): 147–51. http://dx.doi.org/10.14712/18059694.2019.24.

Full text

Abstract:

Possible in vitro inhibition of aromatic amino acid decarboxylase (AAD, EC 4.1.1.28) by a group of phenylsulfonylbenzoic acid derivatives VÚFB 19363, 19369, 19370, 19371, and 19760 as new potential anti-inflammatory compounds was studied using the substrate L-tyrosine. Enzyme inhibition by 2.7x10–5 M concentration of compound VÚFB 19363 (Quinlukast) was 17 %, AAD inhibition at 3.75 x 10–5 M concentration of compounds VÚFB 19369, 19370, 19371, and 19760 ranged between 9–23 %. There were distinct differences between individual compounds. Evaluation of inhibition kinetics suggested full reversibi

APA, Harvard, Vancouver, ISO, and other styles

46

Szotáková, Barbora, Lenka Skálová, Vendula Baliharová, et al. "Characterization of enzymes responsible for biotransformation of the new antileukotrienic drug quinlukast in rat liver microsomes and in primary cultures of rat hepatocytes." Journal of Pharmacy and Pharmacology 56, no. 2 (2004): 205–12. http://dx.doi.org/10.1211/0022357023060.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Ненашева, Н. М., А. Ю. Насунова та М. В. Малышева. "ВЫБОР СТРАТЕГИИ ЛЕЧЕНИЯ АЛЛЕРГИЧЕСКОГО РИНИТА В РЕАЛЬНОЙ КЛИНИЧЕСКОЙ ПРАКТИКЕ". Practical allergology, № 1 (15 травня 2025): 13–26. https://doi.org/10.46393/27129667_2025_13-26.

Full text

Abstract:

Аллергический ринит (АР) – самое распространенное аллергическое заболевание, которому подвержены пациенты всех возрастов. Симптомы АР влияют на различные аспекты качества жизни человека: нарушают сон, эмоциональный фон, производительность труда и способность к обучению. Несмотря на существующие алгоритмы диагностики и лечения АР, существенная часть пациентов не имеет установленного диагноза и не получает адекватную терапию. Цель исследования – определение профилей пациентов с АР, причин направления к врачам-специалистам и критериев выбора терапии. Материал и методы. Проведено исследование в ви

APA, Harvard, Vancouver, ISO, and other styles

48

Kamaev, A. V., O. V. Trusova, I. A. Kamaeva, and N. L. Liashenko. "Allergic rhinitis in children: a comprehensive approach to treatment." Meditsinskiy sovet = Medical Council, no. 1 (March 2, 2022): 184–89. http://dx.doi.org/10.21518/2079-701x-2022-16-1-184-189.

Full text

Abstract:

Prevalence of allergic rhinitis among chronic upper respiratory diseases in pediatrics is one of highest. Beside anti-inflammatory drugs (topical steroids, antileukotrienes, antihistamines), reliever therapies are important too in treatment of allergic rhinitis. Decongestant prescription in children should lasts no more than 7–10 days; combination of alpha1-adrenomimetic with topical antihistamines is one of possible ways to improve the efficacy, for example, the combination of dimetindene maleate with phenylephrine as nasal drops. We present the results of retrospective evaluation of 625 pati

APA, Harvard, Vancouver, ISO, and other styles

49

Зарянкина, А. И. "Bronchial Obstruction Syndrome in Children." Педиатрия. Восточная Европа 12, no. 1 (2024): 142–51. http://dx.doi.org/10.34883/pi.2024.12.1.013.

Full text

Abstract:

Одним из проявлений обструкции дыхательных путей у детей является синдром бронхиальной обструкции, имеющий полиэтиологическую природу, требующий диагностического поиска с целью уточнения причины развития и оказания квалифицированной помощи как для купирования данного патологического состояния, так и лечения основного заболевания, имеющего клинические проявления бронхообструкции. Наиболее часто синдром бронхиальной обструкции у детей является проявлением острой респираторной вирусной инфекции. Немаловажное значение в развитии бронхообструктивного синдрома имеют герпес-вирусы. Инфицированность д

APA, Harvard, Vancouver, ISO, and other styles

50

Rano, Nuraliyeva Shernazarov Farrukh. "USE OF ANTILEUKOTRIENE DRUGS IN PEDIATRICS." October 10, 2023. https://doi.org/10.5281/zenodo.8428357.

Full text

Abstract:

<em>The effects of glucocorticosteroids in the respiratory tract and their systemic effects depend more on the inhalation device used. Given that inflammatory and remodeling processes occur in all parts of the respiratory tract, including distal parts and peripheral bronchioles, regardless of the state of bronchial permeability and compliance with requirements, the optimal method of drug delivery to the lungs the question arises. The preferred particle size of the inhaled drug, which ensures uniform distribution in large and distal bronchi, is 1.0-5.0 μm for adults and 1.1-3.0 μm for chi

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!